01 — At a Glance
The Paradox: Burning Cash on Growth While Your Profits Burn
- 52-Week High / Low₹662 / ₹230
- Q3 FY26 Revenue₹326.6 Cr
- Q3 FY26 PAT₹4.6 Cr
- Annualised EPS (Q1-Q3 Avg × 4)₹4.73
- TTM EPS₹7.28
- Book Value / Share₹73.0
- Price to Book3.87x
- H1 FY26 Revenue₹634.7 Cr
- H1 FY26 PAT₹31.8 Cr
- Order Book (Sep 2025)₹722.2 Cr
Flash Summary: HLE Glascoat shipped ₹326.6 crore revenue in Q3, up 41% YoY. But PAT tanked 46% YoY to ₹4.6 crore because the company’s been on an M&A binge — Kinam, Omeras, integration costs everywhere. H1 FY26 PAT is ₹31.8 crore (60% growth), but the quarterly momentum is flatlining. Order book at ₹722 crore (9 months for intl, 5 months for India) suggests the machine’s well-oiled. The question: when do these acquisitions start printing money instead of eating it?
02 — Introduction
The Specialty Equipment Maker Playing Big
HLE Glascoat is the company that makes the tanks, reactors, and dryers that sit in every pharma and chemical plant in India — and increasingly, in Europe. You don’t see them on TV. No IPL ads. No billboards. But they’re in Bayer, UPL, Sun Pharma, Zydus, Dr. Reddy’s plants, running at full capacity, 24/7.
The business has three main pillars: filtration & drying equipment (39% of sales, >50% market share in India), glass-lined reactors and tanks (49% of sales, 25% market share), and heat transfer equipment (12% of sales, acquired via Kinam). The company’s been reinventing itself every few years — acquired glass-lining business, then Thaletec in Germany (2021), then Kinam (2023), then Omeras (2025). It’s like watching someone collect Infinity Stones, except the stones are manufacturing facilities in three countries.
Here’s the twist: H1 FY26 shows consolidated revenue of ₹634.7 crore (up 37% YoY) and ₹31.8 crore PAT (up 60% YoY). But Q3 standalone revenue is ₹326.6 crore — which means the second quarter did ₹308.1 crore. Do the math: Q2 showed slower revenue, but Q3 spiked. Yet profit in Q3 collapsed to ₹4.6 crore from ₹14.4 crore in Q2. Translation: margin compression from hell.
Concall Insight (Nov 2025): The company explicitly flagged that H1 FY26 growth was driven by “robust order book and inquiries” across all segments. International business visibility stands at 9 months, Indian business at 5 months. They’ve completed the Kinam amalgamation and acquired Omeras, which is expected to add €20–25 crore revenue in FY27. The capex guidance was revised upward to ₹25 crore. Management remained confident on execution despite “integration challenges.” Translator’s note: we’re bleeding money on consolidation, but trust us.
03 — Business Model: WTF Do They Even Do?
Making Metal Containers for Chemists and Pharma Guys to Boil Stuff In
Members get full access to every article.
